

# Cristina Magi-Galluzzi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7764606/publications.pdf>

Version: 2024-02-01

121  
papers

5,713  
citations

109321

35  
h-index

79698

73  
g-index

125  
all docs

125  
docs citations

125  
times ranked

6547  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. <i>European Urology</i> , 2016, 69, 428-435.	1.9	1,039
2	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. <i>European Urology</i> , 2014, 66, 550-560.	1.9	553
3	<i>ERG</i> gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african-american and japanese patients. <i>Prostate</i> , 2011, 71, 489-497.	2.3	239
4	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. <i>Lancet Oncology</i> , The, 2014, 15, 1469-1480.	10.7	226
5	Tuberous Sclerosis-associated Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1457-1467.	3.7	211
6	The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. <i>Histopathology</i> , 2017, 70, 335-346.	2.9	165
7	A Genomic Classifier Improves Prediction of Metastatic Disease Within 5 Years After Surgery in Node-negative High-risk Prostate Cancer Patients Managed by Radical Prostatectomy Without Adjuvant Therapy. <i>European Urology</i> , 2015, 67, 778-786.	1.9	162
8	Development and Clinical Validation of an <i>In Situ</i> Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2591-2600.	7.0	157
9	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	2.5	143
10	Eosinophilic, Solid, and Cystic Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 60-71.	3.7	139
11	Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. <i>Urology</i> , 2016, 90, 148-152.	1.0	138
12	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	5.5	138
13	Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. <i>European Urology</i> , 2015, 68, 555-567.	1.9	125
14	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	5.5	118
15	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. <i>Modern Pathology</i> , 2015, 28, 612-630.	5.5	106
16	Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 279-292.	3.7	101
17	Importance of Additional Extreme-Anterior Apical Needle Biopsies in the Initial Detection of Prostate Cancer. <i>Urology</i> , 2010, 75, 1034-1039.	1.0	90
18	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. <i>Histopathology</i> , 2016, 69, 441-449.	2.9	82

#	ARTICLE	IF	CITATIONS
19	Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. <i>Modern Pathology</i> , 2018, 31, 179-197.	5.5	73
20	Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome. <i>Modern Pathology</i> , 2017, 30, 146-156.	5.5	66
21	Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation. <i>Oncotarget</i> , 2018, 9, 33804-33817.	1.8	65
22	Neoadjuvant docetaxel treatment for locally advanced prostate cancer. <i>Cancer</i> , 2007, 110, 1248-1254.	4.1	55
23	ERG rearrangement is present in a subset of transition zone prostatic tumors. <i>Modern Pathology</i> , 2010, 23, 1499-1506.	5.5	52
24	Eosinophilic solid and cystic renal cell carcinomas have metastatic potential. <i>Histopathology</i> , 2018, 72, 1066-1067.	2.9	49
25	ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. <i>Modern Pathology</i> , 2020, 33, 2564-2579.	5.5	49
26	A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. <i>ELife</i> , 2017, 6, .	6.0	49
27	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019, 25, 210-221.	7.0	48
28	Collecting duct carcinoma of the kidney is associated with <i>CDKN2A</i> deletion and <i>SLC</i> family gene up-regulation. <i>Oncotarget</i> , 2016, 7, 29901-29915.	1.8	47
29	Urothelial Papilloma of the Bladder. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1615-1620.	3.7	46
30	Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer. <i>Cell Reports</i> , 2015, 13, 2135-2146.	6.4	44
31	Acquired Cystic Disease-associated Renal Cell Carcinoma (ACD-RCC). <i>American Journal of Surgical Pathology</i> , 2018, 42, 1156-1165.	3.7	42
32	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. <i>Histopathology</i> , 2015, 67, 313-324.	2.9	41
33	High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex. <i>Histopathology</i> , 2019, 75, 440-442.	2.9	41
34	Perioperative Outcomes of Single vs Multi-Port Robotic Assisted Radical Prostatectomy: A Single Institutional Experience. <i>Journal of Urology</i> , 2020, 204, 490-495.	0.4	41
35	Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. <i>Modern Pathology</i> , 2022, 35, 344-351.	5.5	40
36	Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 141-154.	3.7	39

#	ARTICLE	IF	CITATIONS
37	<i>IFNL4</i> G Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5471-5481.	7.0	37
38	Utility of Pathology Imagebase for standardisation of prostate cancer grading. <i>Histopathology</i> , 2018, 73, 8-18.	2.9	36
39	Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues. <i>Clinical Cancer Research</i> , 2017, 23, 6351-6362.	7.0	35
40	The <i>TMPRSS2</i> - <i>ERG</i> Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1896-1906.	4.1	34
41	Contemporary Gleason grading and novel Grade Groups in clinical practice. <i>Current Opinion in Urology</i> , 2016, 26, 488-492.	1.8	32
42	A novel imaging based Nomogram for predicting post-surgical biochemical recurrence and adverse pathology of prostate cancer from pre-operative bi-parametric MRI. <i>EBioMedicine</i> , 2021, 63, 103163.	6.1	32
43	Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate. <i>American Journal of Surgical Pathology</i> , 2020, 44, 673-680.	3.7	31
44	Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. <i>Annals of Diagnostic Pathology</i> , 2017, 29, 17-22.	1.3	29
45	Multicenter Multireader Evaluation of an Artificial Intelligence-Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI. <i>American Journal of Roentgenology</i> , 2020, 215, 903-912.	2.2	29
46	Single-port robotic partial and radical nephrectomies for renal cortical tumors: initial clinical experience. <i>Journal of Robotic Surgery</i> , 2020, 14, 773-780.	1.8	28
47	Features and Prognostic Significance of Intraductal Carcinoma of the Prostate. <i>European Urology Oncology</i> , 2018, 1, 21-28.	5.4	27
48	TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring <i>MALAT1</i> -TFEB, <i>ACTB</i> -TFEB, and the novel <i>NEAT1</i> -TFEB translocations constantly express PDL1. <i>Modern Pathology</i> , 2021, 34, 842-850.	5.5	26
49	A Genomic Algorithm for the Molecular Classification of Common Renal Cortical Neoplasms: Development and Validation. <i>Journal of Urology</i> , 2015, 193, 1479-1485.	0.4	23
50	Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. <i>European Radiology</i> , 2019, 29, 4861-4870.	4.5	23
51	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. <i>Advances in Anatomic Pathology</i> , 2021, 28, 179-195.	4.3	23
52	Malakoplakia associated with prostatic adenocarcinoma. <i>Annals of Diagnostic Pathology</i> , 2016, 22, 33-37.	1.3	22
53	Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect. <i>Oncotarget</i> , 2016, 7, 33855-33865.	1.8	22
54	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	4.3	20

#	ARTICLE	IF	CITATIONS
55	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables. <i>Cells</i> , 2021, 10, 3166.	4.1	20
56	Pathology Imagebase—a reference image database for standardization of pathology. <i>Histopathology</i> , 2017, 71, 677-685.	2.9	19
57	Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e751-e760.	1.9	17
58	Atrophic Kidney-like Lesion. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1585-1595.	3.7	17
59	Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap. <i>Human Pathology</i> , 2020, 98, 81-88.	2.0	17
60	Single- versus multi-port robotic partial nephrectomy: a comparative analysis of perioperative outcomes and analgesic requirements. <i>Journal of Robotic Surgery</i> , 2022, 16, 695-703.	1.8	17
61	Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas. <i>Modern Pathology</i> , 2021, 34, 2055-2063.	5.5	14
62	Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. <i>Npj Precision Oncology</i> , 2021, 5, 35.	5.4	13
63	Upper tract urinary cytology to detect upper tract urothelial carcinoma: Using the Johns Hopkins Hospital template and evaluation of its feasibility. <i>CytoJournal</i> , 2015, 12, 17.	1.7	13
64	Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical aberration analysis of 12 cases. <i>Annals of Diagnostic Pathology</i> , 2019, 39, 63-68.	1.3	12
65	Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management. <i>Advances in Anatomic Pathology</i> , 2018, 25, 293-303.	4.3	11
66	Clinicopathologic features and outcomes of anterior-dominant prostate cancer: implications for diagnosis and treatment. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 435-440.	3.9	11
67	Robot-assisted ureteral reconstruction using a tubularized peritoneal flap: a novel technique in a chronic porcine model. <i>World Journal of Urology</i> , 2017, 35, 89-96.	2.2	10
68	GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer-Specific Mortality. <i>JCO Precision Oncology</i> , 2021, 5, 442-449.	3.0	10
69	Development of a needle biopsy-based genomic test to improve discrimination of clinically aggressive from indolent prostate cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4560-4560.	1.6	10
70	Impact of 5 $\alpha$ -Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features. <i>Journal of Urology</i> , 2018, 199, 445-452.	0.4	9
71	MicroRNA in prostate cancer: Practical aspects. <i>Histology and Histopathology</i> , 2015, 30, 1379-96.	0.7	9
72	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations. <i>Cells</i> , 2021, 10, 3165.	4.1	9

#	ARTICLE	IF	CITATIONS
73	Low Rate of Cancer Events After Partial Nephrectomy for Renal Cell Carcinoma: Clinicopathologic Analysis of 1994 Cases with Emphasis on Definition of "Recurrence" Clinical Genitourinary Cancer, 2019, 17, 209-215.e1.	1.9	8
74	Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Oncogene, 2019, 38, 4496-4511.	5.9	8
75	Urothelial Carcinoma and its Variants. Surgical Pathology Clinics, 2008, 1, 159-209.	1.7	7
76	Urinary bladder xanthoma: a multi-institutional series of 17 cases. Histopathology, 2015, 67, 255-261.	2.9	7
77	Prostatic Adenocarcinoma, Prostatic Intraepithelial Neoplasia, and Intraductal Carcinoma. Surgical Pathology Clinics, 2008, 1, 43-75.	1.7	6
78	Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine, 2016, 7, 85-93.	6.1	6
79	Squamous Cell Carcinoma of the Bladder Complicating Schistosomiasis: <i>AIRP Best Cases in Radiologic-Pathologic Correlation</i>. Radiographics, 2017, 37, 500-504.	3.3	6
80	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 295.e1-295.e8.	1.6	6
81	Does cumulative prostate cancer length (<sc>CCL</sc>) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?. BJU International, 2015, 116, 220-229.	2.5	5
82	Granular Cell Tumor of the Bladder: A Report of Six Cases. Urology, 2018, 121, 203.e1-203.e5.	1.0	5
83	The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status. Urology, 2018, 121, 132-138.	1.0	5
84	Validation of GEMCaP as a DNA Based Biomarker to Predict Prostate Cancer Recurrence after Radical Prostatectomy. Journal of Urology, 2018, 199, 719-725.	0.4	4
85	Testicular Germ-Cell Tumors with Spermatic Cord Involvement: A Retrospective International Multi-Institutional Experience. Modern Pathology, 2021, , .	5.5	4
86	PD1, PDL1, PDL2 tumor tissue (TT) expression as predictors of response to neoadjuvant chemotherapy (NAC) and outcome in bladder cancer (BC).. Journal of Clinical Oncology, 2016, 34, e16023-e16023.	1.6	4
87	Vascular architectural patterns in clear cell renal cell carcinoma and clear cell papillary renal cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1187-1196.	2.8	4
88	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. American Journal of Cancer Research, 2021, 11, 3990-4001.	1.4	4
89	Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 104.e1-104.e7.	1.6	4
90	PTEN Expression in Mucinous Prostatic Adenocarcinoma, Prostatic Adenocarcinoma With Mucinous Features, and Adjacent Conventional Prostatic Adenocarcinoma: A Multi-institutional Study of 92 Cases. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 225-230.	1.2	3

#	ARTICLE	IF	CITATIONS
91	Older Age at Diagnosis and Initial Disease Volume Predict Grade Reclassification Risk on Confirmatory Biopsy in Patients Considered for Active Surveillance. <i>Urology</i> , 2019, 130, 106-112.	1.0	3
92	High-volume Concurrent Polypoid Ureteritis and Ureteritis Cystica Manifesting With Ureteral Obstruction. <i>Urology</i> , 2020, 136, e7-e11.	1.0	3
93	Pathological characterization and clinical outcome of penile intraepithelial neoplasia variants: a North American series. <i>Modern Pathology</i> , 2022, , .	5.5	3
94	Dehydroepiandrosterone metabolism in fresh human prostate: A feasibility study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 225-225.	1.6	2
95	HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 156-156.	1.6	2
96	Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 382-382.	1.6	2
97	Clinical significance and EZH2, ERG and SPINK1 protein expression in pure and mixed ductal adenocarcinoma of the prostate. <i>Histology and Histopathology</i> , 2019, 34, 381-390.	0.7	2
98	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 495-495.	0.4	2
99	Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 366-372.	1.9	1
100	Effect of neoadjuvant docetaxel treatment for locally advanced prostate cancer on miRNA expression: A pilot study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 139-139.	1.6	1
101	Evidence for a field effect in early prostate cancer (PCa): Gene expression profiles in normal-appearing prostate tissue (NT) adjacent to tumor (T) as predictors of clinical outcome.. <i>Journal of Clinical Oncology</i> , 2013, 31, 5029-5029.	1.6	1
102	Independent validation of a genomic classifier in an at-risk population of men conservatively managed after radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 16-16.	1.6	1
103	Investigating the long noncoding RNA SCHLAP1 as a prognostic tissue and urine biomarker in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7-7.	1.6	1
104	Validation of the Decipher prostate cancer classifier for predicting 10-year postoperative metastasis from analysis of diagnostic needle biopsy specimens.. <i>Journal of Clinical Oncology</i> , 2016, 34, 59-59.	1.6	1
105	A 17-gene genomic prostate score (GPS) as a predictor of biochemical (BCR) and clinical recurrence (CR) in men with surgically treated intermediate- and high-risk prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2016, 34, 104-104.	1.6	1
106	A 17-gene genomic prostate score (GPS) as a predictor of biochemical (BCR) and clinical recurrence (CR) in men with surgically treated intermediate- and high-risk prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5049-5049.	1.6	1
107	Molecular profiling of small cell bladder cancer (SCBC) to reveal gene expression determinants of an aggressive phenotype.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4529-4529.	1.6	1
108	Clinicopathologic Study of Gleason Pattern 5 Prostatic Adenocarcinoma With "Single-cell" Growth Reveals 2 Distinct Types, One With "Plasmacytoid" Features. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1635-1642.	3.7	1

#	ARTICLE	IF	CITATIONS
109	Granulomas associated with renal neoplasms: A multi-institutional clinicopathological study of 111 cases. <i>Histopathology</i> , 2022, , .	2.9	1
110	Differential Expression Patterns of Chicken Ovalbumin Upstream Promoter-Transcription Factor II (COUPTFII) in Primary Renal Cell Neoplasms. <i>American Journal of Clinical Pathology</i> , 2014, 142, A216-A216.	0.7	0
111	Carotenoid 9', 10'-monooxygenase: Tumor Suppressor Activity in Prostate Cancer. <i>FASEB Journal</i> , 2008, 22, 451.6.	0.5	0
112	Identification of prostate cancer-expressed microRNAs associated with clinical recurrence (cR) and prostate cancer-specific survival (PCSS) following radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2012, 30, 21-21.	1.6	0
113	A genomic classifier to improve prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 154-154.	1.6	0
114	Molecular and clinical characterization of 1,577 primary prostate cancer tumors to reveal novel clinical and biological insights into its subtypes.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9-9.	1.6	0
115	<i>HSD3B1</i> and resistance to androgen deprivation therapy in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5020-5020.	1.6	0
116	Evaluation of prognostic factors in upper tract urothelial carcinoma (UTUC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 372-372.	1.6	0
117	Utility of prostate multiparametric MRI (mpMRI) for recurrent prostate cancer after radiation therapy and cryotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 71-71.	1.6	0
118	Patient/treatment characteristics and prognostic factors in small-cell bladder cancer (SCBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16037-e16037.	1.6	0
119	<i>HSD3B1</i> and resistance to androgen deprivation therapy in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5015-5015.	1.6	0
120	Prognostic markers assessment in invasive upper tract urothelial carcinoma (UTUC).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16034-e16034.	1.6	0
121	Validation of GEMCaP as a DNA based biomarker to predict disease recurrence in patients undergoing prostatectomy for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 58-58.	1.6	0